Lexicon Pharma (LXRX) Cash Flow Statement

Click line-items for a historical chart and %

Consolidated net loss	-109.01M
Depreciation	1.55M
Impairment of fixed assets	0
Amortization of Symphony Icon, Inc. purchase option
Change in fair value of Symphony Icon, Inc. purchase liability	-703K
Stock-based compensation	5.72M
Net gain on auction rate securities (“ARS”) and ARS Rights
Gain on disposal of property and equipment	12K
(Increase) decrease in accounts receivable	173K
(Increase) decrease in prepaid expenses and other current assets	7.69M
Decrease in other assets	-25K
Increase (decrease) in accounts payable and other liabilities	18.71M
Decrease in deferred revenue	-51.34M
Net cash used in operating activities	-126.84M
Purchases of property and equipment	-83K
Proceeds from disposal of property and equipment	0
Purchases of investments	-336.65M
Maturities of investments	298.53M
Net cash provided by investing activities	-38.21M
Proceeds from issuance of common stock	2.94M
Repurchase of common stock	-621K
Proceeds from debt borrowings
Repayment of debt borrowings	-1.5M
Net cash provided by (used in) financing activities	827K
Net increase (decrease) in cash and cash equivalents	-164.22M
Cash and cash equivalents at beginning of period	202.99M
Cash and cash equivalents at end of period	38.77M
Cash paid for interest	3.41M
Unrealized gain on investments	297K

Entities mentioned with LXRX

View All Entities